Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ryan Nord

Otolaryngology Richmond, VA Medical Doctor

NPI 1295025328 CMS profile 1395698

1250 E Marshall St, Dept. Of Otolaryngology, Richmond, VA 23298

Open in the dashboard

General payments

$454,497

351 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$27,778 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Ryan Nord of Richmond, VA is reported in the CMS Open Payments database as having received $454,497 across 351 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $27,778 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $65,663 107
2024 General $74,926 113
2023 General $88,377 95
2022 General $103,513 9
2021 General $71,511 7
2020 General $35,596 7
2019 General $14,911 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Nord
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Ryan Nord were reported at $65,663. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Ryan Nord Otolaryngology median Middle half National median
2019 $14,911 $194 $82–$512 $163
2020 $35,596 $118 $42–$280 $114
2021 $71,511 $167 $63–$444 $132
2022 $103,513 $216 $84–$545 $149
2023 $88,377 $235 $93–$588 $160
2024 $74,926 $280 $111–$699 $164
2025 $65,663 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inspire Medical Systems, Inc. $348,509 324 payments
  2. Siesta Medical, Inc. $100,800 6 payments
  3. Hologic, LLC $3,741 4 payments
  4. Intersect ENT, Inc. $680 8 payments
  5. KARL STORZ Endoscopy-America $302 4 payments
  6. Medtronic, Inc. $283 2 payments
  7. Medrobotics Inc. $92 1 payment
  8. Cook Medical LLC $75 1 payment
  9. Lilly USA, LLC $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $387,281 59 payments
  2. Honoraria $23,700 9 payments
  3. Travel and Lodging $18,722 76 payments
  4. Food and Beverage $17,194 206 payments
  5. Education $7,600 1 payment
Products named General payments · program years 2019–2025
  1. INSPIRE $205,327 306 payments
  2. Inspire Upper Airway Stimulation System $143,182 18 payments
  3. Encore $30,800 1 payment
  4. CoolSeal Generator $3,741 4 payments
  5. Encore System $2,800 1 payment
  6. PROPEL $180 7 payments
  7. LigaSure $144 1 payment
  8. BiZact $139 1 payment
  9. IMAGE1 X-LINK $136 1 payment
  10. UNI-ARM SUPPORT SYSTEM $82 1 payment
  11. Other $164 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

70

Median for Otolaryngology: 297

Drug cost

$751

Median for Otolaryngology: $6,314

Branded share of claims

0%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluticasone Propionate Generic 26 $396
Nortriptyline Hcl Generic 12 $158
Omeprazole Generic 19 $134
Trazodone Hcl Generic 13 $62

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$69,592

Medicare's payments for the services billed

Medicare patients

305

Average age 72

Services billed

874

151 women, 154 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 36%
Diabetes 33%
Depression 33%
Chronic kidney disease 21%
COPD 18%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

351 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record